Family Navigation to Improve ADHD Treatment Adherence for Minority Children
Key facts
- Who runs it
- Children's Hospital Medical Center, Cincinnati
- Where
- Cincinnati, United StatesSee the site
- Trial code
- Status
- Completed
- People taking part
- 108 people enrolled
- Started
- 14 May 2021
- Ended
- 30 Jul 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- I2-ART
- Usual care
- Record updated
- 14 August 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Currently providing care for children with ADHD as psychologists, general pediatricians, or developmental pediatricians
- > 18 years old
- Any race/ethnicity
- Having experience working as family navigator and/or community health worker
- Latinx (Lx) or African American (AA)
- > 18 years old
- Phase 1a: current or former caregiver of a child with ADHD, with and without experience with ADHD treatment
- Phases 1b and 2: current caregiver of a child (aged 7-11 years) with ADHD who is ADHD treatment-naïve at study enrollment
- Lx or AA
- > 18 years old
Who cannot take part
- Unable to read/speak either English or Spanish
- Family navigators
- Unable to read/speak either English or Spanish
- Caregivers
- Unable to read/speak either English or Spanish
Other criteria
- Clinicians
Where in United States
- Cincinnati Children's Hospital Medical CenterCincinnati, United States
About the trial
What the trial wants to find out
ADHD is the most common pediatric neurodevelopmental disorder and is associated with significant long-term impairments. Current guidelines recommend stimulant medication and/or behavioral therapy as first-line treatments for ADHD. Despite evidence that consistent treatment is important for effectively managing ADHD symptoms, treatment adherence remains suboptimal and is especially problematic among minority children. Hypothesized reasons for racial/ethnic disparities in ADHD treatment include uncertainties about medication efficacy and side effects, distrust of the health care system, and decreased access to mental health services. This study aims to develop and test the I2-ART intervention to improve treatment adherence in minority (Latinx and African American) children with ADHD. The proposed study involves three ORBIT phases: During phase 1a, the investigators will conduct focus groups with key stakeholders (i.e., caregivers, clinicians, and family navigators, n=24) to identify and develop I2-ART's basic elements. Next, during phase 1b, the investigators will train four family navigators to implement I2-ART with caregivers of treatment-naïve children with ADHD (n=8-12) in order to determine feasibility and acceptability. In phase 2, the investigators will use phase 1b findings to modify I2-ART as needed, and then will evaluate the preliminary efficacy of the revised I2-ART (n=40), compared to the "usual care" control condition (n=20), on ADHD treatment adherence. The preliminary data collected during the proposed study will inform a subsequent R01 randomized controlled trial to examine I2-ART efficacy.
The 2 groups in the trial
- I2-ART GroupExisting treatment, for comparison
I2-ART intervention will be modeled based on the Parent Empowerment Program model. It will use methods of adult learning, direct instruction to share knowledge or techniques for practice, group support, modeling, vicarious learning, and practice opportunities (i.e., role rehearsals). I2-ART training includes 40 hours of didactic and interactive sessions (10 sessions of 4 hours each) covering the following areas: 1) conceptual framework, 2) listening, engagement, and boundary-setting skills; 3) ADHD psychoeducation (e.g., diagnosis, treatment, shared decision-making tools), and 4) service options. The caregivers in the I2-ART group will receive the intervention for 3 months. The I2-ART will be implemented by the family navigators and will include a 2-hour face-to-face meeting, at least three monthly in-person meetings, and intermittent contact between in-person meetings by phone calls, texts or emails, as determined by the family navigator-caregiver dyad.
Treatment: I2-ART
- Control GroupPlacebo, for comparison
The caregivers in the control group will receive "usual care."
Treatment: Usual care
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Family Navigator Intervention to Improve ADHD- Related Treatment Adherence (I2-ART) for Minority Children
- Record updated
- 14 August 2026